Table: The Combatants

All three of America's top cloning companies anticipate windfalls in licensing technology, but their strategies differ in substantial respects

GERON

BUSINESS: Research into the enzyme telomerase as an anticancer agent; study of embryonic stem cells for treating disease; licensing of cloning technology

REVENUES: $3.6 million

ADVANCED CELL TECHNOLOGY

BUSINESS: Cloning animals such as dairy cows; researching the cloning of human embryos for stem-cell production; licensing of cloning technology

REVENUES: $2 million

INFIGEN

BUSINESS: Cloning of cows and pigs; researching animal cloning for production of human therapeutic products

REVENUES: Not disclosed

    Before it's here, it's on the Bloomberg Terminal.
    LEARN MORE